Scarica l'app Stockscreener
0.9201
0.51%
0.0047
Dopo l'orario di chiusura:
.92
-0.000100
-0.01%
Precedente Chiudi:
$0.9154
Aprire:
$0.89
Volume 24 ore:
215.36K
Relative Volume:
0.39
Capitalizzazione di mercato:
$62.33M
Reddito:
-
Utile/perdita netta:
$-46.12M
Rapporto P/E:
-1.0647
EPS:
-0.8642
Flusso di cassa netto:
$-41.02M
1 W Prestazione:
-1.20%
1M Prestazione:
+11.47%
6M Prestazione:
-44.24%
1 anno Prestazione:
-26.39%
Intervallo 1D:
$0.8807
$0.9385
Intervallo di 1 settimana:
$0.8611
$0.9581
Portata 52W:
$0.7113
$1.94
Inflarx N V Stock (IFRX) Company Profile
Compare IFRX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IFRX
Inflarx N V
|
0.9201 | 62.02M | 0 | -46.12M | -41.02M | -0.8642 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Inflarx N V Stock (IFRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-03 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-09-02 | Ripresa | H.C. Wainwright | Buy |
| 2025-05-29 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-04-05 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-02-28 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-10-28 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2021-03-11 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-11-06 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2020-10-08 | Iniziato | H.C. Wainwright | Buy |
| 2020-06-17 | Iniziato | BTIG Research | Buy |
| 2020-04-30 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2019-06-05 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2019-06-05 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-06-05 | Downgrade | JP Morgan | Overweight → Underweight |
| 2019-06-05 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-06-05 | Downgrade | SunTrust | Buy → Hold |
| 2019-01-29 | Iniziato | Robert W. Baird | Outperform |
| 2018-12-10 | Iniziato | Credit Suisse | Outperform |
| 2018-07-13 | Iniziato | BMO Capital Markets | Outperform |
| 2018-06-28 | Iniziato | Raymond James | Outperform |
| 2018-06-28 | Iniziato | SunTrust | Buy |
| 2018-02-08 | Iniziato | B. Riley FBR, Inc. | Buy |
Mostra tutto
Inflarx N V Borsa (IFRX) Ultime notizie
Analysts Set InflaRx N.V. (NASDAQ:IFRX) Target Price at $7.50 - Defense World
IFRX Earnings History & Surprises | EPS & Revenue Results | INFLARX NV (NASDAQ:IFRX) - ChartMill
Aug Macro: Whats the analyst consensus on InflaRx NV2025 Market Sentiment & Community Consensus Stock Picks - baoquankhu1.vn
InflaRx N.V. (NASDAQ:IFRX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
InflaRx Announces Participation in the Leerink Partners Global Healthcare Conference - Bitget
InflaRx Showcases Izicopan HS and CSU Data, Streamlines C5aR Strategy at Oppenheimer Conference - MarketBeat
InflaRx N.V. (IFRX) Presents at Oppenheimer 36th Annual Healthcare Life Sciences ConferenceSlideshow - Seeking Alpha
IFRX Should I Buy - Intellectia AI
IFRX PE Ratio & Valuation, Is IFRX Overvalued - Intellectia AI
InflaRx Spotlights Izicopan HS Data, Phase 2b Plans and 30% Cost Cuts at Guggenheim Summit - MarketBeat
IFRX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Will InflaRx N.V. stock continue dividend increasesJuly 2025 Snapshot & Long-Term Safe Investment Ideas - mfd.ru
Is InflaRx N.V. (IF0) stock among top earnings playsPortfolio Update Summary & Growth Oriented Trading Recommendations - mfd.ru
Treasury Yields: Is InflaRx NV forming bullish engulfing patternsEarnings Risk Summary & Smart Investment Allocation Tips - baoquankhu1.vn
InflaRx N.V. (NASDAQ:IFRX) Receives $7.50 Consensus PT from Analysts - Defense World
Here's Why We're A Bit Worried About InflaRx's (NASDAQ:IFRX) Cash Burn Situation - Sahm
InflaRx N.V. (NASDAQ:IFRX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
InflaRx launches public offering of shares and warrants - MSN
How strong is InflaRx N.V. stock revenue growthWeekly Profit Report & Growth Oriented Trading Recommendations - mfd.ru
InflaRx (NASDAQ:IFRX) Trading 10.4% HigherStill a Buy? - MarketBeat
Here's Why InflaRx (NASDAQ:IFRX) Must Use Its Cash Wisely - Yahoo Finance
History Review: Is InflaRx NV showing insider buyingWeekly Risk Report & Safe Swing Trade Setups - baoquankhu1.vn
Tech Rally: Can InflaRx NV sustain earnings growth2025 EndofYear Setup & Daily Technical Stock Forecast Reports - baoquankhu1.vn
InflaRx Announces Participation in February Investor Conferences - marketscreener.com
Can InflaRx N.V. deliver consistent dividendsTrade Risk Summary & Weekly Market Pulse Alerts - mfd.ru
Biotech firm InflaRx lines up two investor talks in February - Stock Titan
InflaRx NV Explodes After FDA Greenlight: Is IFRX the Biotech Underdog You’re Sleeping On? - AD HOC NEWS
Buyback Watch: Is InflaRx NV showing insider buyingJuly 2025 Levels & Real-Time Market Sentiment Alerts - baoquankhu1.vn
Can InflaRx N.V. (IF0) stock sustain margin levelsMarket Performance Recap & Technical Analysis for Trade Confirmation - bollywoodhelpline.com
Is InflaRx N.V. stock positioned for digital transformationMarket Movers & Safe Entry Point Identification - bollywoodhelpline.com
Meme Stocks: Can InflaRx NV deliver consistent dividends2025 Pullback Review & Safe Entry Momentum Stock Tips - baoquankhu1.vn
Bank Watch: Is Montauk Renewables Inc a potential multi baggerWatch List & Low Drawdown Momentum Ideas - baoquankhu1.vn
Biotech Update: IFRX, ABCL, RLYB Stand Out as Significant Gainers After Hours - Intellectia AI
Bull Run: Why InflaRx N.V. (IF0) stock could rally stronglyJuly 2025 Levels & Weekly High Potential Stock Alerts - Bộ Nội Vụ
InflaRx N.V. (NASDAQ:IFRX) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Pullback Watch: Will InflaRx NV stock recover faster than market2025 Key Highlights & Daily Profit Maximizing Tips - Bộ Nội Vụ
Is InflaRx N.V. stock a top pick in earnings season2025 Fundamental Recap & Intraday High Probability Setup Alerts - Улправда
Why InflaRx N.V. stock remains on buy listsWeekly Investment Recap & Reliable Breakout Stock Forecasts - Улправда
How InflaRx N.V. stock valuations compare to rivalsInflation Watch & Technical Pattern Recognition Alerts - Улправда
InflaRx Cuts Workforce and Refocuses Strategy on Lead Drug Izicopan to Extend Cash Runway to 2027 - TipRanks
Will InflaRx N.V. stock recover faster than market2025 Top Gainers & Advanced Swing Trade Entry Alerts - Улправда
Why is InflaRx Stock Falling Today?InflaRx (NASDAQ:IFRX) - Benzinga
InflaRx stock falls after announcing restructuring and pipeline prioritization By Investing.com - Investing.com India
InflaRx stock falls after announcing restructuring and pipeline prioritization - Investing.com
InflaRx to prioritize izicopan development, cuts workforce by 30% - Investing.com South Africa
InflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation - GlobeNewswire
What analysts say about InflaRx NV IF0 stockPrice Support Zones & Follow Top Performers in the Community - earlytimes.in
InflaRx Reopens Case For Axed Phase 3 Drug For Rare Skin Disorder - Sahm
Weekly Buzz: ARS Pharma's Neffy Goes East, SLS Advances, A Signal Of Hope For IFRX? - RTTNews
Inflarx N V Azioni (IFRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.69%
0.68%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):